J Cancer 2018; 9(22):4294-4300. doi:10.7150/jca.27301 This issue

Research Paper

FABP1 Polymorphisms Contribute to Hepatocellular Carcinoma Susceptibility in Chinese Population with Liver Cirrhosis: A Case-Control Study

Meng Wang1,*, Xinghan Liu2,*, Shuai Lin1, Tian Tian1, Feng Guan3, Yan Guo4, Xiao Li5, Yujiao Deng1, Yi Zheng1, Peng Xu1, Qian Hao1, Zhen Zhai1, Zhijun Dai1✉

1. Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;
2. School of Life Sciences, Nanjing University, Nanjing 210046, China;
3. School of Life Sciences, Northwest University, Xi'an 710069, China;
4. School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China;
5. Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Wang M, Liu X, Lin S, Tian T, Guan F, Guo Y, Li X, Deng Y, Zheng Y, Xu P, Hao Q, Zhai Z, Dai Z. FABP1 Polymorphisms Contribute to Hepatocellular Carcinoma Susceptibility in Chinese Population with Liver Cirrhosis: A Case-Control Study. J Cancer 2018; 9(22):4294-4300. doi:10.7150/jca.27301. Available from https://www.jcancer.org/v09p4294.htm

File import instruction


Purpose: Single nucleotide variations in the liver fatty acid binding protein (L-FABP, FABP1) gene lead to changes in cellular signaling pathways and lipid metabolism. FABP1 polymorphisms were associated with some liver diseases, like steatotic hepatocellular carcinoma. However, the association between FABP1 rs1545224 and rs2241883 polymorphisms and hepatitis B virus-related liver cirrhosis (LC) and hepatocellular carcinoma (HCC) has not been reported. We performed this study to explore their relationship.

Methods: One thousand individuals (250 healthy controls, 250 chronic HBV (CHB), 250 LC, and 250 HCC patients) were recruited. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were applied to assess the difference in allele and genotype frequencies. Cochran-Armitage trend test was used to evaluate the cumulative effect. Significant difference would be defined when the P value was less than 0.05.

Results: The distribution of rs1545224 GG, AG and AA genotypes in healthy controls or CHB carriers was not significant when compared to LC or HCC patients (P>0.05). LC patients carrying at least one A allele are more likely to develop HCC in contrast with those with G allele (P<0.05). After adjustment for confounders, meaningful results were only seen in the comparison between rs1545224 AG+AA genotype carriers and GG genotype carriers among the LC patients (P<0.05). Rs2241883 polymorphism did not influence the risk of developing LC or HCC in healthy and CHB individuals, nor did it influence the risk of HCC in LC patients (P>0.05).

Conclusions: Taken together, FABP1 rs1545224 polymorphism might increase HCC risk in LC patients, indicating that FABP1 rs1545224 polymorphism may be related to the process of developing HCC in Chinese patients with LC.

Keywords: FABP1, polymorphism, hepatocellular carcinoma, liver cirrhosis